Skip to main content
Fig. 1 | Stem Cell Research & Therapy

Fig. 1

From: Co-overexpression of TGF-β and SOX9 via rAAV gene transfer modulates the metabolic and chondrogenic activities of human bone marrow-derived mesenchymal stem cells

Fig. 1

Experimental design. hMSCs were pelleted and divided into nine groups as described in Methods. Group 1, rAAV-lacZ (40 μl); group 2, rAAV-lacZ (40 μl), rAAV-FLAG-hsox9 (40 μl) 1 week later; group 3, rAAV-lacZ (40 μl), rAAV-hTGF-β (40 μl) 1 week later; group 4, rAAV-FLAG-hsox9 (40 μl), rAAV-lacZ (40 μl) 1 week later; group 5, rAAV-FLAG-hsox9 (40 μl), rAAV-hTGF-β (40 μl) 1 week later; group 6, rAAV-hTGF-β (40 μl), rAAV-lacZ (40 μl) 1 week later; group 7, rAAV-hTGF-β (40 μl), rAAV-FLAG-hsox9 (40 μl) 1 week later; group 8, rAAV-hTGF-β (20 μl) concomitant with rAAV-FLAG-hsox9 (40 μl); group 9, rAAV-hTGF-β (40 μl) concomitant with rAAV-FLAG-hsox9 (40 μl). Cultures were maintained for 21 days in chondrogenic medium for further evaluations. ELISA enzyme-linked immunosorbent assay, hMSC human bone marrow-derived mesenchymal stem cell, TGF-β transforming growth factor beta

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512